Alpha-gliadin, a component of gluten proteins found in wheat and related grains, is important in the pathogenesis of celiac disease due to its high proline and glutamine content.
These residues make alpha-gliadin particularly immunogenic, leading to various immune responses in genetically susceptible individuals.
In celiac disease, the immune system produces antibodies including IgA and IgG antibodies against alpha-gliadin peptides, triggering both innate and adaptive immune responses. These include T cell recognition via HLA-DQ2 or HLA-DQ8 molecules and antibody production.
While alpha-gliadin IgG antibodies are a marker for gluten sensitivity and celiac disease, they can also be present in non-celiac gluten sensitivity and other conditions, making them useful but not definitive for diagnosis.
The presence of these antibodies often necessitates further testing, including anti-tissue transglutaminase and endomysial antibodies, to confirm celiac disease.
Alpha-gliadin is one subtype of gliadin. Other subtypes include beta-gliadin, gamma-gliadin and omega-gliadin. [12.]
Alpha-gliadin is a component of gluten proteins found in wheat and related grains. It contains several peptide sequences that are particularly toxic to individuals with celiac disease, known as gliadin toxic peptides.
Alpha-gliadin is considered to be important in the context of celiac disease due to its high content of proline (P) and glutamine (G) residues, which are important in celiac disease pathogenesis. [9.]
The immune response to alpha-gliadins is a complex process that plays a central role in celiac disease pathogenesis. It includes multiple responses by the immune system to various protein and peptide components in sensitive individuals.
Specific components of the immune response include:
Alpha-gliadins contain multiple immunogenic peptides that are recognized by T cells in celiac disease patients.
These peptides bind to HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells, triggering a T cell response.
The most immunogenic alpha-gliadin peptides include the 33-mer peptide and shorter fragments containing overlapping T cell epitopes.
The immune system produces antibodies against alpha-gliadins, including IgA and IgG classes. These antibodies, known as anti-gliadin antibodies (AGAs), are found in the sera of celiac disease patients.
For example, Alpha-Beta Gliadin IgA and IgG antibodies are produced in response to alpha and beta gliadins.
Alpha-gliadin peptides, particularly the p31-43 fragment, can trigger innate immune responses in the intestinal mucosa. This activation leads to the production of pro-inflammatory cytokines and increased intestinal permeability.
tTG plays a crucial role in enhancing the immunogenicity of alpha-gliadin peptides by deamidating specific glutamine residues to glutamic acid. This modification increases the binding affinity of these peptides to HLA-DQ2/8 molecules.
Alpha-gliadins from different wheat genomes (A, B, and D) contain varying combinations of T cell stimulatory epitopes. The D genome-derived alpha-gliadins are generally considered the most immunogenic.
Alpha-gliadin IgG antibodies are a specific class of immunoglobulins produced by the immune system in response to alpha-gliadin, a component of gluten proteins found in wheat and related grains.
While commonly associated with celiac disease, alpha-gliadin IgG antibodies can also be found in some individuals without enteropathy, indicating their presence in other forms of gluten sensitivity. [3., 16.]
The detection of these antibodies is often part of a comprehensive evaluation for gluten-related disorders, although it is not considered a definitive diagnostic test on its own.
Historically, anti-gliadin antibody (AGA) tests were used to diagnose gluten-driven enteropathy, but newer tests assessing for antibodies against deamidated gluten peptides and tissue transglutaminase have shown improved performance. [1., 3.]
However, they may still be used in conjunction with other tests.
However, it's crucial to note that diagnosis of celiac disease or other gluten-related disorders typically requires a combination of serological tests, genetic testing, and often intestinal biopsy, along with clinical evaluation by a healthcare professional.
Anti-gliadin antibodies (AGAs), including alpha-gliadin IgG antibodies, were among the first markers used for celiac disease screening.
However, due to their low specificity and a high percentage of false positives, these tests have largely been replaced by more specific markers such as tissue transglutaminase (tTG) and deamidated gliadin peptides (DGP).
The use of IgG anti-gliadin antibodies, although initially popular, is now limited due to better alternatives in the diagnostic process.
In celiac disease (CD), the production of IgG antibodies against gliadin, including alpha-gliadin, is a significant aspect of the immune response to gluten ingestion.
The pathogenesis of CD involves both innate and adaptive immune responses. The adaptive immune response is primarily mediated by the presentation of deamidated gliadin peptides to T cells by HLA-DQ2 or HLA-DQ8 molecules, which leads to the activation of T-helper cells.
These activated T-helper cells then stimulate B cells to produce various antibodies, including IgA and IgG against gliadin and tissue transglutaminase (tTG).
The production of IgG antibodies against gliadin (AGA-IgG) occurs as part of this adaptive immune response. These antibodies are among the first serological markers to appear in CD patients.
However, AGA-IgG is not highly specific to CD, as these antibodies can also be found in other conditions and in healthy individuals.
Therefore, while AGA can indicate an immune response to gliadin, it is not solely definitive for diagnosing CD without the presence of other more specific markers like tTG or endomysial antibodies (EmA).
In CD, gliadin peptides also trigger an innate immune response, which includes the release of interleukin-15 (IL-15) and other pro-inflammatory cytokines, leading to mucosal damage. This dual immune response—both innate and adaptive—contributes to the characteristic intestinal damage seen in CD, including villous atrophy and crypt hyperplasia.
In the setting of IgA depletion or deficiency, IgG antibodies against gliadin, gliadin peptides and tissue transglutaminase are more reliable than IgA.
IgG anti-gliadin antibodies are found in up to 50% of individuals with non-celiac gluten sensitivity (NCGS). This prevalence is higher compared to the prevalence in individuals with celiac disease (CD). [3.]
In CD, the presence of IgG antibodies, particularly against tissue transglutaminase (tTG) and deamidated gliadin peptides (DGP), is more specific and serves as a key part of the diagnostic criteria.
In contrast, NCGS lacks such specific serological markers, making the diagnosis more challenging and primarily based on symptom resolution upon gluten withdrawal and reappearance upon gluten challenge.
NCGS and CD also show different immune responses to gliadin. In NCGS, IgG AGA typically disappears with strict GFD adherence and correlates with symptom improvement. In contrast, IgG AGA in CD patients persists despite dietary adherence, indicating a sustained autoimmune response. [3.]
In studies examining the effect of a GFD, it was found that AGA levels in NCGS patients decrease significantly after gluten withdrawal, indicating a positive response to the diet.
However, this decrease is more variable and less consistent compared to CD patients. These antibodies tend to persist in CD patients despite long-term withdrawal from gluten.
Testing for the alpha-gliadin IgG typically requires a blood sample to assess for IgG antibodies against this peptide, which often requires a venipuncture. IgG and IgA antibodies are often assessed together to determine whether the individual has mounted an immune response against this gluten-based peptide.
A positive finding in this test should be accompanied or followed with additional assessment including IgA and IgG Anti-Tissue Transglutaminase antibodies and other serological markers.
The presence of IgG antibodies against alpha-gliadin indicates that an immune response has been mounted against these peptides.
Optimal levels of these antibodies are undetectable, or very low.
For reference, one lab reports the following recommended ranges for alpha-gliadin IgG antibodies: [14.]
Gliadin IgG <20 U
Elevated alpha-gliadin IgG antibodies signal a positive immune response against this gluten-based peptide.
Because some individuals can test positive for alpha-gliadin antibodies with no symptoms, results should be interpreted in the context of an individual’s symptom picture.
This may or may not be caused by celiac disease, although further assessment for celiac disease may be warranted, especially if anti-tTG antibodies are also elevated. [3.]
In addition to Alpha-Gliadin IgG antibodies, several other biomarkers are commonly tested in the evaluation of celiac disease and gluten-related disorders.
Tissue transglutaminase (tTG) is an enzyme that catalyzes the deamidation of gliadin peptides, increasing their immunogenicity. In individuals with HLA-DQ2 or HLA-DQ8 genes, the deamidated gluten peptides are presented to CD4+ T cells, triggering an adaptive immune response. [6.]
This leads to the activation of both T cells and B cells, resulting in the production of antibodies against gluten (anti-gliadin) and tTG (anti-tTG).
Antibodies against tTG are highly specific for celiac disease and are the most widely used serological marker for diagnosis.
Both IgA and IgG anti-tTG antibodies can be measured, although the IgA isotype is more often high (except in the setting of IgA depletion or deficiency), so an anti-tTG IgA antibody test is considered the most sensitive and specific. [7.]
Deamidated gliadin peptides (DGPs), including the Alpha-Gliadin-17-mer, are the primary targets of the autoimmune response in celiac disease.
Levels of these antibodies may rise before anti-tTG antibodies, making them useful in the diagnosis of early celiac disease. [10.]
Antibodies against DGPs can be useful in diagnosing celiac disease, especially in patients with IgA deficiency or in children younger than 2 years old.
Endomysial antibodies (EMA) are directed against the endomysial component of smooth muscle, which is rich in tTG.
EMA testing has high specificity for celiac disease but lower sensitivity compared to anti-tTG and anti-DGP antibodies. It is often used as a confirmatory test in conjunction with other serological markers.
Alpha-Gliadin is a component of gluten, which is a group of proteins found in wheat and related grains such as barley and rye. It is one of the primary proteins that can trigger an immune response in individuals with celiac disease.
Immunoglobulin G (IgG) is a type of antibody that plays a vital role in the body's immune response. It is the most abundant antibody in the blood and is critical for fighting bacterial and viral infections.
Alpha-Gliadin IgG refers to IgG antibodies that are produced in response to alpha-gliadin, a component of gluten. These antibodies are measured in blood tests to help diagnose celiac disease and other gluten-related disorders, although sometimes they are seen in asymptomatic patients.
Alpha-Gliadin IgG is significant in celiac disease because the presence of these antibodies indicates an immune response to gluten. Elevated levels of Alpha-Gliadin IgG antibodies are a marker for a gluten sensitivity.
Historically they were a marker helping in the diagnosis of celiac disease, although recently other serology markers and biopsy are used in diagnosis of celiac disease.
Alpha-Gliadin IgG is detected through a blood test.
A positive Alpha-Gliadin IgG test indicates that the immune system is reacting to alpha-gliadin, suggesting that the individual may have developed an immune response to gluten.
Further testing, including additional serology as well as consideration of a biopsy of the small intestine, is usually required to confirm the diagnosis of celiac disease.
Symptoms of celiac disease can vary widely but often include:
Celiac disease is typically diagnosed through a combination of blood tests and a biopsy of the small intestine to confirm damage to the intestinal villi.
The primary treatment for celiac disease is a strict, lifelong gluten-free diet. This involves avoiding all foods that contain wheat, barley, rye, and their derivatives to prevent symptoms and intestinal damage.
Alpha-Gliadin IgG levels can remain elevated in individuals with celiac disease; therefore, they are not always useful in monitoring treatment success.
However, in individuals with non-celiac gluten sensitivity, IgG levels may decrease over time, making this an appropriate tool for monitoring treatment in this population.
Alpha-Gliadin is found in gluten-containing foods, which include products made from wheat, barley, and rye. This includes bread, pasta, cereals, and many processed foods.
To avoid Alpha-Gliadin, individuals with celiac disease should follow a strict gluten-free diet.
This involves reading food labels carefully, choosing naturally gluten-free foods (such as fruits, vegetables, and unprocessed meats), and selecting gluten-free alternatives for common gluten-containing foods.
For more information about Alpha-Gliadin IgG and celiac disease, consider consulting:
Click here to compare testing options and order testing to assess for gluten sensitivity.
[1.] Anti Gliadin Antibody Assay. www.myadlm.org. Published March 21, 2023. Accessed June 20, 2024. https://www.myadlm.org/advocacy-and-outreach/optimal-testing-guide-to-lab-test-utilization/a-f/anti-gliadin-antibody-assay
[2.] Barone MV, Troncone R, Auricchio S. Gliadin peptides as triggers of the proliferative and stress/innate immune response of the celiac small intestinal mucosa. Int J Mol Sci. 2014 Nov 7;15(11):20518-37. doi: 10.3390/ijms151120518. PMID: 25387079; PMCID: PMC4264181.
[3.] Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, Fasano A. Celiac disease: a comprehensive current review. BMC Med. 2019 Jul 23;17(1):142. doi: 10.1186/s12916-019-1380-z. PMID: 31331324; PMCID: PMC6647104.
[4.] Celiac Disease Foundation. Celiac Disease Screening | Celiac Disease Foundation. Celiac Disease Foundation. Published 2018. https://celiac.org/about-celiac-disease/screening-and-diagnosis/screening/
[5.] Cummins A, Thompson F. Sensitivity of anti-endomysial antibody in detecting celiac disease. Gastroenterology. 2002;122(1):246-247. doi:https://doi.org/10.1053/gast.2002.30908
[6.] De Re V, Magris R, Cannizzaro R. New Insights into the Pathogenesis of Celiac Disease. Frontiers in Medicine. 2017;4. doi:https://doi.org/10.3389/fmed.2017.00137
[7.] Gliadin (Deamidated) Antibody, IgG, Serum - Mayo Clinic Laboratories | Pediatric Catalog. Testcatalog.org. Published 2020. Accessed June 20, 2024. https://pediatric.testcatalog.org/show/DGGL
[8.] Goebel S. Celiac Disease (Sprue): Practice Essentials, Background, Pathophysiology. EMedicine. Published online December 2, 2019. https://emedicine.medscape.com/article/171805-overview
[9.] Japelj N, Suligoj T, Zhang W, Côrte-Real B, Messing J, Ciclitira PJ. Natural variants of α-gliadin peptides within wheat proteins with reduced toxicity in coeliac disease. British Journal of Nutrition. 2020;123(12):1382-1389. doi:10.1017/S0007114520000768
[10.] Lammi A, Pekka Arikoski, Satu Simell, et al. Antibodies to Deamidated Gliadin Peptide in Diagnosis of Celiac Disease in Children. Journal of Pediatric Gastroenterology and Nutrition. 2015;60(5):626-631. doi:https://doi.org/10.1097/mpg.0000000000000666
[11.] Mayo Clinic. Celiac Disease - Symptoms and Causes. Mayo Clinic. Published September 12, 2023. https://www.mayoclinic.org/diseases-conditions/celiac-disease/symptoms-causes/syc-20352220
[12.] Mefleh M, Motzo R, Samson M, Morel MH, Giunta F. N Partitioning between Gluten Fractions in a Set of Italian Durum Wheat Cultivars: Role of the Grain N Content. 2020;9(11):1684-1684. doi:https://doi.org/10.3390/foods9111684
[13.] Mitea C, Salentijn EMJ, van Veelen P, et al. A Universal Approach to Eliminate Antigenic Properties of Alpha-Gliadin Peptides in Celiac Disease. Uversky VN, ed. PLoS ONE. 2010;5(12):e15637. doi:https://doi.org/10.1371/journal.pone.0015637
[14.] Rupa Health. Celiac & Gluten Sensitivity Serum Sample Report.pdf. Google Docs. Accessed June 20, 2024. https://drive.google.com/file/d/1wWbHgtWCIc9V0Q_JLiapOg9ZF61UNuo6/view
[15.] Sayed SK, Imam HM, Mahran AM, Refaiy AM. Diagnostic utility of deamidated gliadin peptide antibody in celiac disease compared to anti-tissue transglutaminase and IgA- endomysium antibodies. Egypt J Immunol. 2012;19(2):41-52. PMID: 23885406.
[16.] ten Dam M, Van De Wal Y, Mearin ML, Kooy Y, Peña S, Drijfhout JW, Koning F, Van Tol M. Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin. Clin Exp Immunol. 1998 Nov;114(2):189-95. doi: 10.1046/j.1365-2249.1998.00722.x. PMID: 9822275; PMCID: PMC1905116.
[17.] Vojdani A, Vojdani E. Gluten and non-gluten proteins of wheat as target antigens in autism, Crohn’s and celiac disease. Journal of Cereal Science. 2017;75:252-260. doi:https://doi.org/10.1016/j.jcs.2017.04.010